The association between lifestyle factors and mental illness (MI) in college-going women.
Alnylam reveals positive Phase III results for rare heart disease drug vutrisiran – Pharmaceutical Technology
RNAi therapeutic, vutrisiran is FDA approved for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTR) in adults and is sold under the brand name